Datum CV Therapeutics to Announce 2003 Fourth Quarter and Year End ... 02.02.2004 22:10
PALO ALTO, Calif., Feb. 2 /PRNewswire-FirstCall/ -- CV Therapeutics, Inc. today announced that it will release fourth quarter and year end financial results for 2003 after the market closes on Tuesday, February 10, 2004. Company management will webcast a conference call at 5:30 p.m. EST, 2:30 p.m. PST, on the company``s website.
To access the live webcast, please log on to the company``s website at http://www.cvt.com/ and go to the Investor Information section. Alternatively, domestic callers may participate in the conference call by dialing 888-370-6121, and international callers may participate in the conference call by dialing 706-679-7163. Webcast and telephone replays of the conference call will be available approximately two hours after the completion of the call through Tuesday, February 17, 2004. Domestic callers can access the replay by dialing 800-642-1687, and international callers can access the replay by dialing 706-645-9291; the PIN access number is 5336322.
About CV Therapeutics
CV Therapeutics, Inc., headquartered in Palo Alto, California, is a biopharmaceutical company focused on applying molecular cardiology to the discovery, development and commercialization of novel, small molecule drugs for the treatment of cardiovascular diseases. CV Therapeutics currently has four compounds in clinical development. If approved by the FDA, Ranexa(TM) would represent the first new class of anti-anginal therapy in more than 25 years. Regadenoson (CVT-3146), a selective A2A-adenosine receptor agonist, is being developed for potential use as a pharmacologic stress agent in cardiac perfusion imaging studies. Tecadenoson, an A1-adenosine receptor agonist, is being developed for the potential reduction of rapid heart rate during atrial arrhythmias. Adentri(TM), an A1-adenosine receptor antagonist for the potential treatment of acute and chronic congestive heart failure, is licensed to Biogen, Inc. (now Biogen Idec). For more information, please visit CV Therapeutics`` website at http://www.cvt.com/.
CV Therapeutics, Inc.
© PR Newswire
Gruß Seinfeld
